Nivolumab Appears Safe, Effective in Wild-Type, Mutant BRAF Melanoma
the Cancer Therapy Advisor take:
Nivolumab has similar efficacy and safety outcomes in patients with wild-type or mutant BRAF metastatic melanoma, regardless of prior treatment with a BRAF inhibitor or ipilimumab, a recent study published in JAMA Oncology.
For the study, researchers conducted a pooled analysis from four clinical trials of nivolumab that included 440 adult patients with unresectable stage III or stage IV melanoma. All patients had been tested for BRAF mutational status and results showed that 334 were BRAF wild-type and 106 were BRAF V600 mutation-positive. The majority of patients received nivolumab 3mg/kg intravenously over 60 minutes every 2 weeks until disease progression, unacceptable toxicity, withdrawal, or end of study.
Results showed that the objective response rates were 34.6% (95% CI: 28.3-41.3) for the 217 evaluable patients with wild-type BRAF status and 29.7% (95% CI: 19.7-41.5) for the 74 evaluable patients with mutant BRAF status. Researchers found that objective response rates were not impacted by prior therapy with a BRAF inhibitor, ipilimumab, or PD-L1 tumor status.
In regard to safety, treatment-related adverse events of any grade occurred in 68.3% in the wild-type BRAF group compared with 58.5% in the mutant BRAF group.
Nivolumab has similar efficacy and safety outcomes in patients with wild-type or mutant BRAF metastatic melanoma.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- A Vegan Diet and Cancer
- As HPV-Related Cancer Rates Climb, Experts Scrutinize Barriers to HPV Vaccination
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- Duvelisib Delayed Progression in CLL/SLL: Study
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Prostate Cancer Drug Treatments
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Lenalidomide Induces Immunity, Produces Clinical Response in CLL
- Comorbidities Signal Worse Outcomes in CLL After Targeted Treatment
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- Immune-Related Adverse Events Due to Checkpoint Inhibition Are More Common in Melanoma Than in NSCLC
- Potential Diagnostic Tool Detects BCR-ABL1 mRNA in Chronic Myeloid Leukemia